Skip to content

DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

The Accuracy of Host DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening: a Multi-center, Double-blind, Parallel Controlled Clinical Trials

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05290922
Enrollment
7150
Registered
2022-03-22
Start date
2022-03-12
Completion date
2023-03-12
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Screening, Cervical Cytology, DNA Methylation, Endometrial Cancer, Testing Accuracy

Brief summary

Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening. This study would provide profound basis for the approval of assay kit of DNA methylation in China for endometrial screening. Four hospitals, including Peking Union Medical College Hospital, would enroll eligible patients in this study. The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. The methylation testing would be double-blinded in operators and analysts. The study will enroll at least 7150 patients.

Interventions

The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.

Sponsors

Obstetrics & Gynecology Hospital of Fudan University
CollaboratorOTHER
The Third Xiangya Hospital of Central South University
CollaboratorOTHER
Women's Hospital School Of Medicine Zhejiang University
CollaboratorOTHER
Lei Li
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* With uerine and uterine cervix intact * Aged 18 years or older * With accessible histological results of endometrium * Signed an approved informed consents * With accessible cervical cytology before harvesting endometrial histology

Exclusion criteria

* Not meeting all of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of methylation testingOne weekSensitivity of methylation testing of cervical cytology compared with histology
Specificity of methylation testingOne weekSpecificity of methylation testing of cervical cytology compared with histology

Secondary

MeasureTime frameDescription
Positive predictive value of methylation testingOne weekPositive predictive value of methylation testing of cervical cytology compared with histology
Negative predictive value of methylation testingOne weekNegative predictive value of methylation testing of cervical cytology compared with histology

Countries

China

Contacts

Primary ContactLei Li, M.D
lileigh@163.com10-139-1198-8831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026